Physicochemical characteristics of citrus jelly with non cariogenic and functional sweeteners

In this study the effect of sweeteners with low glycemic index and non-cariogenic characteristics (isomaltulose, oligofructose and tagatose) in jelly prepared with citrus juice has been evaluated considering a citrus jelly formulated with sucrose as reference. The soluble solids, moisture content, pH, water activity, antioxidant capacity, optical and mechanical properties of jelly made using different sweeteners was determined during storage. Besides, mesophilic aerobics and moulds and yeasts was also counted to determine their stability over time. Sensory evaluation of the citrus jelly has also been done. The results showed the antioxidant activity decreased during storage in all formulations. Tagatose increased lightness whereas coordinates a*, b* and chrome of all the jellies prepared using new sweeteners were lower than jellies with sucrose. However, citrus jelly with only oligofructose or tagatose or with the mixture of isomaltulose and tagatose were most closely resembled to the control jelly with respect to mechanical properties. Jelly prepared with the combination of isomaltulose and tagatose in equal proportions obtained the best score in the sensorial analysis.The authors would like to thank the Serigo-Andres family for donating the raw materials, and also the GVA projects GV/2013/029, GV/2014/012 as well as the Universitat Politecnica de Valencia (Spain) for the financial support given to this research study (UPV PAID-06-12 SP20120889).Rubio-Arraez, S.; Capella Hernández, JV.; Castelló Gómez, ML.; Ortolá Ortolá, MD. (2016). Physicochemical characteristics of citrus jelly with non cariogenic and functional sweeteners. Journal of Food Science and Technology. 53(10):3642-3650. https://doi.org/10.1007/s13197-016-2319-4S364236505310Álvarez J, Pastoriza S, Alonso-Olalla R, Delgado-Andrade C, Rufián-Henares JA (2014) Nutritional and physicochemical characteristic of commercial Spanish citrus juices. Food Chem 164:396–405AOAC (2000) Official methods of analysis of AOAC international, 17th edn. Gaithersburg, MDCalzada-León R, Ruiz-Reyes ML, Altamirano-Bustamante N, Padrón-Martínez MM (2013) Features of the noncaloric sweeteners and their use in children. Acta Pediatr Méx 34(3):141–153Chacón-Villalobos A (2006) Current perspectives agribusiness oligofructosaccharides (FOS). Agron Mesoam 17(2):265–286De Oliva-Neto P, Menão PTP (2009) Isomaltulose production from sucrose by protaminobacter rubrum immobilized in calcium alginate. Bioresour Technol 100:252–4256de Queiroz Pane D, Dias CB, Meinhart AD, Ballus CA, Godoy HT (2015) Evaluation of the sweetener content in diet/light/zero foods and drinks by HPLC-DAD. J Food Sci Tech 52(11):6900–6913Edwards WP (2002) The science of goodies. Acribia S.A, SpainFood and Drug Administration (FDA) (2005) GRAS Notification Isomaltulose (PALATINOSE). http://www.fda.gov/ucm/groups/fdagov-public/@fdagovfoodsgen/documents/document/ucm268989.pdf . Accessed 12 July 2015Food and Drug Administration (FDA) (2010) GRAS Notification Tagatose. GRN No.352. http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-foods-gen/documents/document/ucm269560.pdf . Accessed 12 July 2015Food and Drug Administration (FDA) (2011) GRAS Notification Oligofructose. GRN No.392. http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-foodsgen/documents/document/ucm277112.pdf . Accessed 12 July 2015GME (2015) Gelatine manufactured Europe gelatine properties. http://www.gelatine.org/en/about-gelatine/properties.html . Accessed 12 July 2015ISO (2003) Sensory analysis. Guidelines for the use of quantitative response scales [ref. no.ISO 4121:2003]. International Organization for Standardization, GenevaISO (2008) Sensory analysis Vocabulary [ref. no.ISO 5492:2008]. International Organization for Standardization, GenevaLedur MJ, Tessaro I, Zapata CP (2013) Physicochemical characterization of Saccharides Powder obtained from Yacon Roots (Smallanthus sonchifolius) by membrane technology. Braz Arch Biol Technol 56(6):1024–1033Levin GV (2002) Tagatose, the new GRAS sweetener and health product. J Med Food 5(1):23–36Lina BAR, Jonker G, Kozianowski G (2002) Isomaltulose (Palatinose review of biological and toxicologycal studies). Food Chem Toxicol 40(10):1375–1381O’Donnell K, Kearsley M (2012) Sweeteners and sugar alternatives in food technology, 2nd edn. Wiley, ChichesterOh DK (2007) Tagatose: properties, applications, and biotechnological processes. Appl Microb Biotechnol 76(1):1–8Pacual MR, Calderón-Pascual V (2000) Food Microbiology. Analytical methodology for foods and drinks, 2nd edn. Diaz de Santos, MadridPeinado I, Rosa E, Heredia A, Andrés A (2012) Rheological characteristics of healthy sugar substituted spreadable strawberry product. J Food Eng 113(3):365–373Peinado I, Rosa E, Heredia A, Escriche I, Andrés A (2013) Optical, mechanical and sensorial properties of strawberry spreadable products formulated with isomaltulose. Food Bioprocess Tech 6(9):2353–2364Periche A, Heredia A, Escriche I, Andrés A, Castelló ML (2014) Optical, mechanical and sensory properties of based-isomaltulose gummy confections. Food Biosci 7:37–44Periche A, Heredia A, Escriche I, Andrés A, Castelló ML (2015a) Potential use of isomaltulose to produce healthier marshmallows. LWT-Food Sci Technol 62(1):605–612Periche Á, Castelló ML, Heredia A, Escriche I (2015b) Stevia rebaudiana, Oligofructose and isomaltulose as sugar replacers in Marshmallows: stability and antioxidant properties. J Food Process Preserv. doi: 10.1111/jfpp.12653Petersen-Skytte U (2006) Tagatose. In: Mitchell H (ed) Sweeteners and sugar alternatives in food technology. Blackwell Publishing, Oxford, pp 262–292Pimentel TC, Madrona GS, Prudencio SH (2015) Probiotic clarified apple juice with oligofructose or sucralose as sugar substitutes: sensory profile and acceptability. LWT–Food. Sci Technol 62(1):838–846Rababah TM, Al-Mahasneh MA, Kilani I, Yang W, Alhamad MN, Ereifeja E, Al-U’datta M (2011) Effect of jam processing and storage on total phenolics, antioxidant activity, and anthocyanins of different fruits. J Sci Food Agric 91:1096–1102Rubio-Arraez S, Sahuquillo S, Capella JV, Ortolá MD, Castelló ML (2015) Influence of healthy sweeteners (Tagatose and Oligofructose) on the physicochemical characteristics of orange marmalade. J Texture Stud 46(4):272–280Shahidi F, Liyana-Pathirana CM, Wall DS (2006) Antioxidant activity of white and black sesame seeds and their hull fractions. Food Chem 99(3):478–483Shukla V, Kandra P (2015) Development, physico-chemical and sensory evaluation of natural nutra candy. J Food Sci Tech Mys 52(11):7535–7539Taylor TP, Fasina O, Bell LN (2008) Physical properties and consumer liking of cookies prepared by replacing sucrose with tagatose. J Food Sci 73(3):145–151Van Den Heuvel EGHM, Muys T, Van Dokkum W, Schaafsma G (1999) Oligofructose stimulates calcium absorption in adolescents. Am J Clinic Nutr 69:544–548Vastenavond CM, Bertelsen H, Hansen SJ, Laursen RS, Saunders J, Eriknauer K (2012) Tagatose (D-tagatose). In: Nabors L (ed) Alternative sweeteners. Boca Ratón, Florida, USA, p 197–222Zeng Y, Zhang X, Guan Y, Sun Y (2012) Enzymatic hydrolysates from tuna backbone and the subsequent Maillard reaction with different ketohexoses. Int J Food Sci Technol 47:1293–130

Association of genomic domains in BRCA1 and BRCA2 with prostate cancer risk and aggressiveness

Pathogenic sequence variants (PSV) in BRCA1 or BRCA2 (BRCA1/2) are associated with increased risk and severity of prostate cancer. Weevaluated whether PSVs inBRCA1/2 were associated with risk of overall prostate cancer or high grade (Gleason 8+) prostate cancer using an international sample of 65 BRCA1 and 171 BRCA2 male PSV carriers with prostate cancer, and 3,388 BRCA1 and 2,880 BRCA2 male PSV carriers without prostate cancer. PSVs in the 30 region of BRCA2 (c.7914+) were significantly associated with elevated risk of prostate cancer compared with reference bin c.1001c.7913 [HR = 1.78; 95% confidence interval (CI), 1.25-2.52; P = 0.001], as well as elevated risk of Gleason 8+ prostate cancer (HR = 3.11; 95% CI, 1.63-5.95; P = 0.001). c.756-c.1000 was also associated with elevated prostate cancer risk (HR = 2.83; 95% CI, 1.71-4.68; P = 0.00004) and elevated risk of Gleason 8+prostate cancer (HR = 4.95; 95% CI, 2.12-11.54; P = 0.0002). No genotype-phenotype associations were detected for PSVs in BRCA1. These results demonstrate that specific BRCA2 PSVs may be associated with elevated risk of developing aggressive prostate cancer. Significance: Aggressive prostate cancer risk in BRCA2 mutation carriers may vary according to the specific BRCA2 mutation inherited by the at-risk individual.Peer reviewe

GWAS meta-analysis of intrahepatic cholestasis of pregnancy implicates multiple hepatic genes and regulatory elements

Intrahepatic cholestasis of pregnancy (ICP) is a pregnancy-specific liver disorder affecting 0.5–2% of pregnancies. The majority of cases present in the third trimester with pruritus, elevated serum bile acids and abnormal serum liver tests. ICP is associated with an increased risk of adverse outcomes, including spontaneous preterm birth and stillbirth. Whilst rare mutations affecting hepatobiliary transporters contribute to the aetiology of ICP, the role of common genetic variation in ICP has not been systematically characterised to date. Here, we perform genome-wide association studies (GWAS) and meta-analyses for ICP across three studies including 1138 cases and 153,642 controls. Eleven loci achieve genome-wide significance and have been further investigated and fine-mapped using functional genomics approaches. Our results pinpoint common sequence variation in liver-enriched genes and liver-specific cis-regulatory elements as contributing mechanisms to ICP susceptibility

Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis

Background Rare genetic variants cause pulmonary arterial hypertension, but the contribution of common genetic variation to disease risk and natural history is poorly characterised. We tested for genome-wide association for pulmonary arterial hypertension in large international cohorts and assessed the contribution of associated regions to outcomes. Methods We did two separate genome-wide association studies (GWAS) and a meta-analysis of pulmonary arterial hypertension. These GWAS used data from four international case-control studies across 11744 individuals with European ancestry (including 2085 patients). One GWAS used genotypes from 5895 whole-genome sequences and the other GWAS used genotyping array data from an additional 5849 individuals. Cross-validation of loci reaching genome-wide significance was sought by meta-analysis. Conditional analysis corrected for the most significant variants at each locus was used to resolve signals for multiple associations. We functionally annotated associated variants and tested associations with duration of survival. All-cause mortality was the primary endpoint in survival analyses. Findings A locus near SOX17 (rs10103692, odds ratio 1·80 [95% CI 1·55–2·08], p=5·13×10– ¹⁵) and a second locus in HLA-DPA1 and HLA-DPB1 (collectively referred to as HLA-DPA1/DPB1 here; rs2856830, 1·56 [1·42–1·71], p=7·65×10– ²⁰) within the class II MHC region were associated with pulmonary arterial hypertension. The SOX17 locus had two independent signals associated with pulmonary arterial hypertension (rs13266183, 1·36 [1·25–1·48], p=1·69×10– ¹²; and rs10103692). Functional and epigenomic data indicate that the risk variants near SOX17 alter gene regulation via an enhancer active in endothelial cells. Pulmonary arterial hypertension risk variants determined haplotype-specific enhancer activity, and CRISPR-mediated inhibition of the enhancer reduced SOX17 expression. The HLA-DPA1/DPB1 rs2856830 genotype was strongly associated with survival. Median survival from diagnosis in patients with pulmonary arterial hypertension with the C/C homozygous genotype was double (13·50 years [95% CI 12·07 to >13·50]) that of those with the T/T genotype (6·97 years [6·02–8·05]), despite similar baseline disease severity. Interpretation This is the first study to report that common genetic variation at loci in an enhancer near SOX17 and in HLA-DPA1/DPB1 is associated with pulmonary arterial hypertension. Impairment of SOX17 function might be more common in pulmonary arterial hypertension than suggested by rare mutations in SOX17. Further studies are needed to confirm the association between HLA typing or rs2856830 genotyping and survival, and to determine whether HLA typing or rs2856830 genotyping improves risk stratification in clinical practice or trials. Funding UK NIHR, BHF, UK MRC, Dinosaur Trust, NIH/NHLBI, ERS, EMBO, Wellcome Trust, EU, AHA, ACClinPharm, Netherlands CVRI, Dutch Heart Foundation, Dutch Federation of UMC, Netherlands OHRD and RNAS, German DFG, German BMBF, APH Paris, INSERM, Université Paris-Sud, and French ANR

Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness

Pathogenic sequence variants (PSV) in BRCA1 or BRCA2 (BRCA1/2) are associated with increased risk and severity of prostate cancer. We evaluated whether PSVs in BRCA1/2 were associated with risk of overall prostate cancer or high grade (Gleason 8þ) prostate cancer using an international sample of 65 BRCA1 and 171 BRCA2 male PSV carriers with prostate cancer, and 3,388 BRCA1 and 2,880 BRCA2 male PSV carriers without prostate cancer. PSVs in the 3 0 region of BRCA2 (c.7914þ) were significantly associated with elevated risk of prostate cancer compared with reference bin c.1001c.7913 [HR ¼ 1.78; 95% confidence interval (CI), 1.25–2.52; P ¼ 0.001], as well as elevated risk of Gleason 8þ prostate cancer (HR ¼ 3.11; 95% CI, 1.63–5.95; P ¼ 0.001). c.756-c.1000 was also associated with elevated prostate cancer risk (HR ¼ 2.83; 95% CI, 1.71–4.68; P ¼ 0.00004) and elevated risk of Gleason 8þ prostate cancer (HR ¼ 4.95; 95% CI, 2.12–11.54; P ¼ 0.0002). No genotype–phenotype associations were detected for PSVs in BRCA1. These results demonstrate that specific BRCA2 PSVs may be associated with elevated risk of developing aggressive prostate cancer